1,089 results

#75033-AAV9

Ready-to-use AAV9 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

Sept. 27, 2023

Academic Institutions and Nonprofits only

#139505-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

Oct. 28, 2021

Academic Institutions and Nonprofits only

#137139-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-ChR2(ET/TC)-EYFP (#137139). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-ChR2(ET/TC)-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of ChR2(E123T/T159C)-EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 19, 2021

Academic Institutions and Nonprofits only

#22222-AAV1

Ready-to-use AAV1 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chow et al Nature. 2010 Jan 7. 463(7277):98-102.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#105555-AAV9

Ready-to-use AAV9 particles produced from pENN.AAV.hSyn.Cre.hGH (#105555). In addition to the viral particles, you will also receive purified pENN.AAV.hSyn.Cre.hGH plasmid DNA. hSyn driven Cre expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

July 26, 2018

Academic Institutions and Nonprofits only

#55639-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-fDIO hChR2(H134R)-EYFP (#55639). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO hChR2(H134R)-EYFP plasmid DNA. Ef1a-driven, Flp-dependent expression of ChR2(H134R)-EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 7, 2025

Academic Institutions and Nonprofits only

#83900-AAV5

Ready-to-use AAV5 particles produced from pAAV-mDlx-GFP-Fishell-1 (#83900). In addition to the viral particles, you will also receive purified pAAV-mDlx-GFP-Fishell-1 plasmid DNA. mDlx-driven expression of GFP in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Aug. 25, 2023

Academic Institutions and Nonprofits only

#59170-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Syn-Chronos-GFP (#59170). In addition to the viral particles, you will also receive purified pAAV-Syn-Chronos-GFP plasmid DNA. Chronos-GFP under the control of the Synapsin promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Oct. 3, 2017

Academic Institutions and Nonprofits only

#98930-AAV5

Ready-to-use AAV5 particles produced from pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 (#98930). In addition to the viral particles, you will also receive purified pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 plasmid DNA. GFAP-driven glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

Feb. 27, 2018

Academic Institutions and Nonprofits only

#111066-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-dLight1.1 (#111066). In addition to the viral particles, you will also receive purified pAAV-hSyn-dLight1.1 plasmid DNA. hSyn-driven expression of dLight1.1 dopamine sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

Oct. 28, 2021

Academic Institutions and Nonprofits only

#100841-AAV5

Ready-to-use AAV5 particles produced from pAAV.Syn.GCaMP6m.WPRE.SV40 (#100841). In addition to the viral particles, you will also receive purified pAAV.Syn.GCaMP6m.WPRE.SV40 plasmid DNA. Syn-driven GCaMP6m calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

April 17, 2018

Academic Institutions and Nonprofits only

#137955-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.iAChSnFR (#137955). In addition to the viral particles, you will also receive purified pAAV.CAG.iAChSnFR plasmid DNA. CAG-driven iAChSnFR acetylcholine sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Borden et al bioRxiv 2020

Oct. 28, 2021

Academic Institutions and Nonprofits only

#104496-PHPeB

Ready-to-use AAV PHP.eB particles produced from pGP-AAV-CAG-FLEX-jGCaMP7f-WPRE (#104496). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP7f-WPRE plasmid DNA. CAG-driven, Cre-dependent jGCaMP7f calcium sensor. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Sept. 27, 2023

Academic Institutions and Nonprofits only

#99039-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

May 15, 2019

Academic Institutions and Nonprofits only

#137151-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-NpHR3.3-EYFP (#137151). In addition to the viral particles, you will also receive purified pAAV-nEF-NpHR3.3-EYFP plasmid DNA. nEF-driven expression of NpHR3.3-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 5, 2021

Academic Institutions and Nonprofits only

#65417-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-dF-HA-KORD-IRES-mCitrine (#65417). In addition to the viral particles, you will also receive purified pAAV-hSyn-dF-HA-KORD-IRES-mCitrine plasmid DNA. hSyn-driven, Cre-dependent KORD expression with bicistronic mCitrine, for SALB-induced neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Vardy et al Neuron. 2015 Apr 29. pii: S0896-6273(15)

Feb. 6, 2026

Academic Institutions and Nonprofits only

#179459-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-DIO-JEDI-2P-Kv-WPRE (#179459). In addition to the viral particles, you will also receive purified pAAV-EF1a-DIO-JEDI-2P-Kv-WPRE plasmid DNA. EF1a-driven, Cre-dependent soma and AIS-localized expression of voltage indicator JEDI-2P. These AAV preparations are suitable purity for injection into animals.

Francois St-Pierre

Liu et al Cell. 2022 Aug 16. pii: S0092-8674(22)00

Aug. 23, 2022

Academic Institutions and Nonprofits only

#105548-AAV8

Ready-to-use AAV8 particles produced from pENN.AAV.CMVs.TurboRFP.WPRE.RBG (#105548). In addition to the viral particles, you will also receive purified pENN.AAV.CMVs.TurboRFP.WPRE.RBG plasmid DNA. CMV-driven TurboRFP expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 29, 2018

Academic Institutions and Nonprofits only

#162380-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-CAG-FLEX-jGCaMP8s-WPRE (#162380). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP8s-WPRE plasmid DNA. CAG-driven, Cre-dependent expression of calcium sensor GCaMP8s (more sensitive). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

June 22, 2021

Academic Institutions and Nonprofits only

#105322-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-FLEX-jGCaMP7c variant 1513-WPRE (#105322). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP7c variant 1513-WPRE plasmid DNA. Synapsin-driven, Cre-dependent jGCaMP7c expression. jGCaMP7c exhibits high contrast between peak fluorescence and resting fluorescence. It is useful for activity imaging of large populations of densely-labeled neurons because background fluorescence from inactive neurons is reduced. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

June 13, 2019

Academic Institutions and Nonprofits only

#230681-AAV5

Ready-to-use AAV5 particles produced from AiP1636 - pAAV-AiE2116m-minBG-iCre-WPRE-BGHpA (#230681). In addition to the viral particles, you will also receive purified AiP1636 - pAAV-AiE2116m-minBG-iCre-WPRE-BGHpA plasmid DNA. minBG-driven expression of iCre recombinase in specific populations of brain cells. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Bosiljka Tasic

Ben-Simon et al Cell. 2025 May 16:S0092-8674(25)00513-6.

Aug. 6, 2025

Academic Institutions and Nonprofits only

#213945-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe4_ChR2_mCherry (#213945). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the SST interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#158757-AAV8

Ready-to-use AAV8 particles produced from pAAV-CAG-SomaGCaMP6f2 (#158757). In addition to the viral particles, you will also receive purified pAAV-CAG-SomaGCaMP6f2 plasmid DNA. CAG-driven expression of soma-targeting GCaMP6f2. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Shemesh et al Neuron. 2020 Jun 26. pii: S0896-6273(20)

Feb. 23, 2021

Academic Institutions and Nonprofits only

#213943-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe3_GCaMP6f (#213943). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the PV+ basket cell-targeting enhancer E3. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#105547-AAVrg

Ready-to-use AAV Retrograde particles produced from pENN.AAV.EF1a.eGFP.WPRE.rBG (#105547). In addition to the viral particles, you will also receive purified pENN.AAV.EF1a.eGFP.WPRE.rBG plasmid DNA. EF1a-driven EGFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Oct. 18, 2021

Academic Institutions and Nonprofits only

#218792-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_dTomato_nlsdTomato (#218792). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the Lamp5 interneuron-targeting enhancer. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#119036-AAV1

Ready-to-use AAV1 particles produced from pAAV-hsyn-flex-Voltron-ST (#119036). In addition to the viral particles, you will also receive purified pAAV-hsyn-flex-Voltron-ST plasmid DNA. Synapsin-driven, cre-dependent expression of genetically encoded fluorescent voltage indicator Voltron1 with a soma-targeting sequence. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Abdelfattah et al Science. 2019 Aug 1. pii: science.aav641

April 10, 2019

Academic Institutions and Nonprofits only

#183519-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE (#183519). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE plasmid DNA. CaMKIIa-driven expression of ChRmine-oScarlet-KV 2.1. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Kishi et al Cell. 2022 Feb 17;185(4):672-689.e23. do

Dec. 18, 2024

Academic Institutions and Nonprofits only

#196219-AAV2

Ready-to-use AAV2 particles produced from pAAV.CAG.FLEX.iGluSnFR3.v857.PDGFR (#196219). In addition to the viral particles, you will also receive purified pAAV.CAG.FLEX.iGluSnFR3.v857.PDGFR plasmid DNA. CAG-driven, Cre-dependent third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Aggarwal et al Nat Methods. 2023 May 4. doi: 10.1038/s4

Aug. 6, 2025

Academic Institutions and Nonprofits only

#26975-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-hChR2(H134R)-mCherry (#26975). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-mCherry plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#176267-AAV1

Ready-to-use AAV1 particles produced from pAAV-FLEX-P301L Tau (#176267). In addition to the viral particles, you will also receive purified pAAV-FLEX-P301L Tau plasmid DNA. EF1a-driven, Cre-dependent expression of human 2N4R microtubule-associated protein tau with P301L mutation. These AAV preparations are suitable purity for injection into animals.

Tsuneya Ikezu

You et al Neuroscience. 2019 Dec 1;422:65-74. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#232837-AAV8

Ready-to-use AAV8 particles produced from pAAV-Syn-NES-SomaFRCaMPi (#232837). In addition to the viral particles, you will also receive purified pAAV-Syn-NES-SomaFRCaMPi plasmid DNA. Synapsin-driven SomaFRCaMPi calcium sensor. These AAV preparations are suitable purity for injection into animals.

Kiryl Piatkevich

Zhou et al PLoS Biol. 2025 Apr 29;23(4):e3003048. d

Jan. 15, 2026

Academic Institutions and Nonprofits only

#137133-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-mCherry (#137133). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-mCherry plasmid DNA. EF1a-driven, Cre-dependent expression of mCherry (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 5, 2021

Academic Institutions and Nonprofits only

#106174-AAV9

Ready-to-use AAV9 particles produced from pAAV.hSynapsin.SF-iGluSnFR.A184S (#106174). In addition to the viral particles, you will also receive purified pAAV.hSynapsin.SF-iGluSnFR.A184S plasmid DNA. hSynapsin driven SF-iGluSnFR.A184S glutamate sensor. The A184S mutant has a higher glutamate affinity. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Feb. 14, 2024

Academic Institutions and Nonprofits only

#98929-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn.iGluSnFr.WPRE.SV40 (#98929). In addition to the viral particles, you will also receive purified pAAV.hSyn.iGluSnFr.WPRE.SV40 plasmid DNA. Synapsin-driven, iGluSnFr glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

Feb. 27, 2018

Academic Institutions and Nonprofits only

#183412-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CAG-FlpO (#183412). In addition to the viral particles, you will also receive purified pAAV-CAG-FlpO plasmid DNA. CAG-driven expression of the recombinase FlpO. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Janelia Viral Tools

March 27, 2024

Academic Institutions and Nonprofits only

#140558-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_rDA-mut (#140558). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_rDA-mut plasmid DNA. Synapsin-driven expression of control red fluorescent dopamine sensor GRAB_rDA-mut (does not respond to DA). These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 31, 2021

Academic Institutions and Nonprofits only

#68720-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn1-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA (#68720). In addition to the viral particles, you will also receive purified pAAV-hSyn1-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA plasmid DNA. Cre-dependent GCaMP6s calcium sensor and bicistronic, physically separate mRuby2 expression under a human synapsin1 promoter. These AAV preparations are suitable purity for injection into animals.

Tobias Bonhoeffer, Mark Huebener, Tobias Rose

Rose et al Science. 2016 Jun 10;352(6291):1319-22.

March 7, 2018

Academic Institutions and Nonprofits only

#26968-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

Feb. 20, 2018

Academic Institutions and Nonprofits only

#137126-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Fon-sRGECO (#137126). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-sRGECO plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of cytosolic sRGECO calcium sensor. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 5, 2021

Academic Institutions and Nonprofits only

#105534-AAV8

Ready-to-use AAV8 particles produced from pAAV.TBG.PI.LacZ .bGH (#105534). In addition to the viral particles, you will also receive purified pAAV.TBG.PI.LacZ .bGH plasmid DNA. TBG-driven expression of LacZ. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

July 27, 2018

Academic Institutions and Nonprofits only

#137149-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-Arch3.3-EYFP (#137149). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-Arch3.3-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of Arch3.3-EYFP (inhibited in presence of Flp) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#191737-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP12610 - pAAV-AiE0780m-minBG-SYFP2-WPRE3-BGHpA (Alias: CN2610) (#191737). In addition to the viral particles, you will also receive purified AiP12610 - pAAV-AiE0780m-minBG-SYFP2-WPRE3-BGHpA (Alias: CN2610) plasmid DNA. minBG-driven expression of SYFP2 in striatal direct pathway medium spiny neurons (D1-MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2024

Academic Institutions and Nonprofits only

#175274-AAV1

Ready-to-use AAV1 particles produced from pAAV-rtTA (#175274). In addition to the viral particles, you will also receive purified pAAV-rtTA plasmid DNA. Syn-driven expression of reverse tetracycline-controlled transactivator. These AAV preparations are suitable purity for injection into animals.

Wei Xu

Li et al Nat Methods. 2021 Nov 25. pii: 10.1038/s

Jan. 15, 2026

Academic Institutions and Nonprofits only

#125560-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-dLight1.3b (#125560). In addition to the viral particles, you will also receive purified pAAV-CAG-dLight1.3b plasmid DNA. CAG-driven expression of dLight1.3b dopamine sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

May 6, 2021

Academic Institutions and Nonprofits only

#176761-AAV9

Ready-to-use AAV9 particles produced from pZac2.1-GfaABC1D-lck-jGCaMP8s (#176761). In addition to the viral particles, you will also receive purified pZac2.1-GfaABC1D-lck-jGCaMP8s plasmid DNA. GfaABC1D-driven expression of membrane-bound calcium sensor GCaMP8s. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#154948-AAVrg

Ready-to-use AAV Retrograde particles produced from CaMKII-somBiPOLES-mCerulean (#154948). In addition to the viral particles, you will also receive purified CaMKII-somBiPOLES-mCerulean plasmid DNA. CamKII-driven expression of soma-targeted BiPOLES for optogenetic inhibition (blue light) and activation (red light). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Simon Wiegert

Vierock et al Nat Commun. 2021 Jul 26;12(1):4527. doi:

Sept. 1, 2021

Academic Institutions and Nonprofits only

#135429-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-Flex-Axon-EGFP (#135429). In addition to the viral particles, you will also receive purified pAAV-hSyn-Flex-Axon-EGFP plasmid DNA. Syn-driven, Cre-dependent expression of axon-targeted EGFP control. These AAV preparations are suitable purity for injection into animals.

Rylan Larsen

March 19, 2021

Academic Institutions and Nonprofits only

#112005-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 (#112005). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 plasmid DNA. Synapsin-driven, axon-targeted GCaMP6s calcium sensor and mRuby3 expression. The mRuby3 will be a separate protein (not a fusion protein). These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Dec. 4, 2018

Academic Institutions and Nonprofits only

#137143-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2-mCherry (#137143). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2-mCherry plasmid DNA. nEF-driven, Cre-dependent expression of ChR2-mCherry for optogenetic activation (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Feb. 25, 2021

Academic Institutions and Nonprofits only